Nuformix PLC (LSE: NFX) said it has filed a second patent application for a new family of co-crystalline forms of a drug already on the market which has achieved sales of over Â£ 1 billion in 2020.
The application covers the company’s NXP004 reformulation of the unnamed product.
Chief Executive Officer Anne Brindley said: âThe data we have generated on these new forms of co-crystal over the past six months has shown improvements over the marketed form that justifies the filing of this new application.
âThis request, if successful, will strengthen the patent area for NXP004 and Nuformix’s intellectual property portfolio as a whole. “
The company specializes in the conversion or improvement of existing treatments.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is …
In return for the publishing services rendered by the Company on behalf of the persons named herein, including the promotion by the Company of any Content on the Site, the Company receives from this issuer annual cash …
FOR OUR FULL DISCLAIMER CLICK HERE